Oculis Holding AG (OCS) 10-Year Financial Performance & Capital Metrics

OCS • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesOphthalmology & Ocular Diseases

AboutOculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.Show more

Revenue $686K
EBITDA -$73M +9.5%
Net Income -$86M +3.4%
EPS (Diluted) -2.12 +28.6%
Gross Margin -7492.27%
EBITDA Margin -10611.95%
Operating Margin -10671.14%
Net Margin -12503.94%
ROE -102.66% -8.4%
ROIC -106.75% +45.9%
Debt/Equity 0.02 +149.1%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading near 52-week high

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 35.1% in last year
✗Expensive at 13.1x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-49.52%

EPS CAGR

10Y-

5Y-

3Y-

TTM-23.73%

ROCE

10Y Avg-88.82%

5Y Avg-88.82%

3Y Avg-100.52%

Latest-85.43%

Peer Comparison

Ophthalmology & Ocular Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KPRXKiora Pharmaceuticals, Inc.	8.05M	2.19	2.52		22.47%	-38.12%	100%	0.00
KALAKALA BIO, Inc.	16.74M	0.60	-0.09		-141.11%	-388.29%		2.62
CLSDClearside Biomedical, Inc.	5.81M	1.11	-0.16	-79.77%	-7.81%
OTLKOutlook Therapeutics, Inc.	33.47M	0.52	-0.29		-25.93%
ADVMAdverum Biotechnologies, Inc.	96.26M	4.36	-0.66	-72.22%	-130.93%	-189.84%		1.30
IRDOpus Genetics, Inc.	143.45M	2.08	-0.97	-42.3%	-466.09%	-11.43%
SKYESkye Bioscience, Inc.	30.87M	0.96	-1.32			-156.01%		0.01
ALDXAldeyra Therapeutics, Inc.	265.32M	4.41	-4.69			-87.71%		0.22

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	686K
Revenue Growth %	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	52.08M
COGS % of Revenue	-	-	-	-	75.92%
Gross Profit+	0	0	0	0	-51.4M
Gross Margin %	-	-	-	-	-74.92%
Gross Profit Growth %	-	-	-	-	-
Operating Expenses+	12.34M	13.23M	32.38M	80.71M	21.81M
OpEx % of Revenue	-	-	-	-	31.79%
Selling, General & Admin	3.52M	4.1M	6.74M	14.72M	21.81M
SG&A % of Revenue	-	-	-	-	31.79%
Research & Development	9.34M	9.57M	22.22M	29.25M	52.08M
R&D % of Revenue	-	-	-	-	75.92%
Other Operating Expenses	-516K	-433K	3.41M	36.74M	-52.08M
Operating Income+	-12.34M	-13.23M	-32.38M	-80.71M	-73.2M
Operating Margin %	-	-	-	-	-106.71%
Operating Income Growth %	-	-0.07%	-1.45%	-1.49%	0.09%
EBITDA+	-12.11M	-13M	-32.08M	-80.43M	-72.8M
EBITDA Margin %	-	-	-	-	-106.12%
EBITDA Growth %	-	-0.07%	-1.47%	-1.51%	0.09%
D&A (Non-Cash Add-back)	228K	235K	299K	287K	406K
EBIT	-12.34M	-13.4M	-32.2M	-87.38M	-73.2M
Net Interest Income+	-2.62M	-5.1M	-6.32M	126.86K	1.53M
Interest Income	10K	21K	126K	1.59M	1.53M
Interest Expense	2.63M	5.12M	6.44M	1.46M	0
Other Income/Expense	-2.45M	-5.29M	-6.27M	-7.98M	-12.73M
Pretax Income+	-14.79M	-18.52M	-38.64M	-88.69M	-85.94M
Pretax Margin %	-	-	-	-	-125.27%
Income Tax+	83K	27K	55K	107K	-160K
Effective Tax Rate %	1.01%	1%	1%	1%	1%
Net Income+	-14.87M	-18.55M	-38.7M	-88.8M	-85.78M
Net Margin %	-	-	-	-	-125.04%
Net Income Growth %	-	-0.25%	-1.09%	-1.29%	0.03%
Net Income (Continuing)	-14.87M	-18.55M	-38.7M	-88.8M	-85.78M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-0.45	-0.57	-1.18	-2.97	-2.12
EPS Growth %	-	-0.27%	-1.07%	-1.52%	0.29%
EPS (Basic)	-0.45	-0.57	-1.18	-2.97	-2.12
Diluted Shares Outstanding	32.73M	32.73M	32.73M	29.9M	40.41M
Basic Shares Outstanding	32.73M	32.73M	32.73M	29.9M	40.41M
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	6.16M	47.98M	23.66M	101.02M	104.9M
Cash & Short-Term Investments	4.95M	46.28M	19.79M	91.65M	98.66M
Cash Only	4.95M	46.28M	19.79M	38.33M	27.71M
Short-Term Investments	0	0	0	53.32M	70.95M
Accounts Receivable	1.14M	0	0	7.95M	777K
Days Sales Outstanding	-	-	-	-	413.42
Inventory	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-
Other Current Assets	1K	911K	1.08M	0	0
Total Non-Current Assets+	10.22M	10.06M	13.4M	13.34M	15.46M
Property, Plant & Equipment	1.44M	1.29M	1.12M	1.04M	1.69M
Fixed Asset Turnover	-	-	-	-	0.41x
Goodwill	0	0	0	0	0
Intangible Assets	8.72M	8.72M	12.21M	12.21M	13.29M
Long-Term Investments	50K	0	0	0	0
Other Non-Current Assets	0	52K	74K	89K	476K
Total Assets+	16.38M	58.04M	37.06M	114.35M	120.35M
Asset Turnover	-	-	-	-	0.01x
Asset Growth %	-	2.54%	-0.36%	2.09%	0.05%
Total Current Liabilities+	4.34M	4.06M	12.02M	19.09M	44.23M
Accounts Payable	790K	824K	3.87M	7.6M	5.87M
Days Payables Outstanding	-	-	-	-	41.14
Short-Term Debt	0	0	0	0	0
Deferred Revenue (Current)	1000K	0	0	1000K	0
Other Current Liabilities	-1K	0	1	-497K	19.85M
Current Ratio	1.42x	11.81x	1.97x	5.29x	2.37x
Quick Ratio	1.42x	11.81x	1.97x	5.29x	2.37x
Cash Conversion Cycle	-	-	-	-	-
Total Non-Current Liabilities+	55.7M	114.94M	123.03M	1.54M	2.73M
Long-Term Debt	53.98M	113.5M	122.45M	0	0
Capital Lease Obligations	645K	577K	491K	431K	865K
Deferred Tax Liabilities	0	0	0	0	0
Other Non-Current Liabilities	1.07M	857K	91K	1.11M	1.87M
Total Liabilities	60.04M	119M	135.05M	20.63M	46.97M
Total Debt+	54.81M	114.27M	123.08M	605K	1.18M
Net Debt	49.86M	68M	103.3M	-37.72M	-26.53M
Debt / Equity	-	-	-	0.01x	0.02x
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-4.69x	-2.58x	-5.03x	-55.16x	-
Total Equity+	-43.65M	-60.95M	-97.99M	93.73M	73.38M
Equity Growth %	-	-0.4%	-0.61%	1.96%	-0.22%
Book Value per Share	-1.33	-1.86	-2.99	3.13	1.82
Total Shareholders' Equity	-43.65M	-60.95M	-97.99M	93.73M	73.38M
Common Stock	297K	335K	39K	366K	446K
Retained Earnings	-53.73M	-72.28M	-110.98M	-199.78M	-285.56M
Treasury Stock	-100K	-100K	-1K	0	-10K
Accumulated OCI	-1.37M	656K	2.21M	-1.4M	-2.5M
Minority Interest	0	0	0	0	0

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-12.03M	-13.82M	-25.07M	-53.84M	-47.5M
Operating CF Margin %	-	-	-	-	-69.24%
Operating CF Growth %	-	-0.15%	-0.81%	-1.15%	0.12%
Net Income	-14.79M	-18.52M	-38.64M	-88.69M	-85.94M
Depreciation & Amortization	228K	235K	299K	287K	406K
Stock-Based Compensation	328K	328K	804K	3.61M	9.78M
Deferred Taxes	47K	0	0	0	0
Other Non-Cash Items	2.61M	4.93M	6.47M	43.95M	14.09M
Working Capital Changes	-451K	-791K	6M	-12.99M	14.16M
Change in Receivables	10K	233K	-152K	36K	247K
Change in Inventory	-10K	0	0	0	0
Change in Payables	-649K	30K	3.04M	3.73M	-1.71M
Cash from Investing+	-19K	-28K	-3.55M	-54.21M	-17.56M
Capital Expenditures	-19K	-28K	-65K	-48K	-230K
CapEx % of Revenue	-	-	-	-	0.34%
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	0	0	-3.48M	0	0
Cash from Financing+	4.86M	55.19M	1.71M	129.67M	54.03M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	-68K	-804K	-157K	-5.79M	763K
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-12.05M	-13.85M	-28.62M	-53.89M	-47.73M
FCF Margin %	-	-	-	-	-69.58%
FCF Growth %	-	-0.15%	-1.07%	-0.88%	0.11%
FCF per Share	-0.37	-0.42	-0.87	-1.80	-1.18
FCF Conversion (FCF/Net Income)	0.81x	0.75x	0.65x	0.61x	0.55x
Interest Paid	0	0	0	0	0
Taxes Paid	0	0	0	0	0

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-94.74%	-102.66%
Return on Invested Capital (ROIC)	-149.11%	-149.85%	-393.39%	-197.47%	-106.75%
Gross Margin	-	-	-	-	-7492.27%
Net Margin	-	-	-	-	-12503.94%
Debt / Equity	-	-	-	0.01x	0.02x
Interest Coverage	-4.69x	-2.58x	-5.03x	-55.16x	-
FCF Conversion	0.81x	0.75x	0.65x	0.61x	0.55x

Frequently Asked Questions

Growth & Financials

Oculis Holding AG (OCS) reported $0.5M in revenue for fiscal year 2024.

Oculis Holding AG (OCS) grew revenue by 0.0% over the past year. Growth has been modest.

Oculis Holding AG (OCS) reported a net loss of $104.1M for fiscal year 2024.

Dividend & Returns

Oculis Holding AG (OCS) has a return on equity (ROE) of -102.7%. Negative ROE indicates the company is unprofitable.

Oculis Holding AG (OCS) had negative free cash flow of $61.4M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener